Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170587 | 0.84 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL8315325 | 0.84 | PPARG (0.69) | PPARGPPARA | |
| SCHEMBL28417484 | 0.83 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL3409853 | 0.82 | PPARG (0.59) | PPARGPPARA | |
| SCHEMBL11501300 | 0.80 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL295888 | 0.80 | SMN1; SMN2 (0.64) | PPARGPPARA | |
| SCHEMBL4300663 | 0.80 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL4651839 | 0.80 | SMN1; SMN2 (0.64) | PPARGPPARA | |
| SCHEMBL11204807 | 0.80 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL27688923 | 0.80 | PPARG (0.57) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110143932-A | Piperazinone derivs and preparation method thereof, inhibitor and the method for preventing and treating root parasitism weeds | 南开大学 | 2019-08-20 | — | — | CN | disclosed |
| EP-1283825-B1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-6812237-B2 | (ARYLAMINOACEAMIDO)ACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| EP-1283825-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | Novartis AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087828-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2001-11-22 | — | — | WO | disclosed |
| EP-0786701-A1 | RESIST COMPOSITION | NIPPON ZEON CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
| US-4668698-A | [(4-phenyl-1,3-dioxan-cis-5-yl)alkyl]phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | CTSS, CTSV, CTSF | PPARG 2607/4885PPARA 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.